Upgrade to Buy: Q1 Momentum and Sector Tailwinds Put Galderma in a New Growth Phase
Galderma (GALDY) looks like a buy after price action and sector data point to multi-engine growth acceleration: aesthetics, prescription dermatology and self-care are all showing secular strength. Technical momentum, L'Oréal's increased stake and outsized short activity create a favorable risk/reward for a disciplined long trade. Entry $44.00, stop…